Strategy
Contract Research organisations
An Outlook
Financial performance of large innovative pharmaceutical companies in indicated a gloomy prospect for these wellestablished leaders in their domain This trend is expected to grow as many drugs are going offpatent in time to come
The Six Great Shifts
Transforming the pharma industry
Many languages have an equivalent to the expression Seeing the forest for the trees meaning the ability to discern the big picture from little details That ability is important in life but especially true for leaders of life sciences sector Every day we are bombarded with news of innovative technology tighter regulation and new approaches to contro...
The New Education for Future Pharma & Biotech Leaders
The New Education for Future Pharma & Biotech Leaders
Leading pharma or biotech executives often hold degrees in science including medicine or in business For scientists who are interested in pursuing careers in management one hurdle is to acquire the knowledge and skills necessary to excel in a business environment and for exe
Metabolic Biomarker and Target Discovery in Obesity-Associated Comorbidities
Metabolic Biomarker and Target Discovery in Obesity-Associated Comorbidities
Millions of adults are diagnosed as obese each year worldwide Many of these people suffer from a disorder known as metabolic syndrome which includes symptoms such as hypertension and elevated blood cholesterol They are also at risk of developing additional diseases such as heart disease and diabetes mellitus Obesity may in fact be a major cause of...
Open Source Drug Discovery
A feasible business model?
Open source model in the pharma industry is currently used by nonprofit organisations and governments to discover drugs for diseases neglected by industry It is hoped that the open source model can be suitably adapted by the pharma industry and used as a sustainable business model to discover costefficient drugs and to offer other tangible benefits...
Innovation
The key growth mantra
Innovation which is expected to be the leading growth driver has made the Indian life sciences industry focus on building their portfolios of speciality and niche drugs or entering into alliances with the innovator companies to tap this key business opportunity Indian life sciences industry is making constant efforts to have a thrust on innovation...
The Arab Drug Industry
Challenges and future potential
In response to the st century challenges to the health sector WHO established an important global commission on Macroeconomics and Health One of the important conclusions of the commission report indicated that by the year the world could save up to million lives every year by scaling up access to existing health interventions to prevent or treat...
New Patents for Old Drugs
Label-based strategies in the United States
In recent years particularly since the Dotcom stock market crash in venture capitalists have been increasingly reluctant to fund US companies engaging in drug development Such investments are often considered to be too risky too capitalintensive and to take too long to fit the new more conservative venture capital model Indeed it has been estimate...
Pharma and Biotech
Collaborative models
Collaborations are the voluntary joint actions of two or more parties to achieve a common goal This is a straightforward concept in principle but often more complex in the real world Within the pharmaceutical and biotechnology sectors one can easily identify at least six major classes of stakeholders viz private industry academia regulatory agen...
Breaking Down Borders
Asian biotechnology industry
If you had run into Mark Engel CEO and founder of Excel PharmaStudies at the recent China Pharmaceutical RD Summit at Shanghai you would realise that even the young biotech industry in Asia is not immune to the rapid globalisation of drug discovery and development Excel a leading CRO was started by a western businessman in China and serves custome...
